🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs
5,568

Quick answer

Oncology: NovaPharmaNews indexes 5,568 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Page 93 of 116

  1. Camrelizumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Pancreatic Cancer

    phase 1 small molecule active

    1 trial

  2. Camsirubicin

    Monopar Therapeutics

    Advanced Soft-tissue Sarcoma

    phase 1 small molecule terminated

    1 trial

  3. Canagliflozin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Colorectal Cancer

    phase 1 small molecule active

    1 trial

  4. Cardiac safety of treosulfan chemotherapy prior to stem cell transplantation in patients with leukemia.

    Medac Gesellschaft fuer klinische Spezialpraeparate mbH

    Subjects with AML ( Acute myeloid leukaemia) or MDS (Myelodysplastic syndrome) undergoing allogeneic hematopoietic stem cell transplantation

    phase 1 other active

    1 trial

  5. Carfilzomib

    Lxo Ireland Designated Activity Company

    Acute Lymphoblastic Leukemia (ALL)

    phase 1 small molecule completed

    1 trial

  6. Carmustine

    ADC Therapeutics SA

    Recurrent Diffuse Large B-Cell Lymphoma

    phase 1 small molecule terminated

    1 trial

  7. Cemiplimab

    Regeneron UK Limited

    Hormone Receptor-positive Breast Cancer

    phase 1 small molecule completed

    1 trial

  8. Cemiplimab

    Regeneron UK Limited

    Locally Advanced Head and Neck Squamous Cell Carcinoma

    phase 1 small molecule active

    1 trial

  9. Cemiplimab

    Regeneron UK Limited

    Lung Cancer

    phase 1 small molecule active

    1 trial

  10. Cemiplimab

    Regeneron UK Limited

    Advanced Cancer

    phase 1 small molecule completed

    1 trial

  11. Cemiplimab

    Regeneron UK Limited

    Anaplastic Thyroid Cancer

    phase 1 mab active

    1 trial

  12. Cemiplimab

    Regeneron UK Limited

    Epithelial Ovarian Cancer

    phase 1 small molecule active

    1 trial

  13. Cemiplimab-Rwlc

    Regeneron UK Limited

    Merkel Cell Carcinoma

    phase 1 small molecule active

    1 trial

  14. Ceralasertib, IMFINZI 50 mg/mL concentrate for solution for infusion, INFLIXIMAB, MYCOPHENOLATE MOFETIL, AZD4773, IMJUDO 20 mg/ml concentrate for solution for infusion.

    AstraZeneca AB

    • Non-small cell lung cancer (Stage III, unresectable) • Small cell lung cancer (Limited stage) • Hepatocellular carcinoma (Unresectable) • Advanced or Metastatic non-small cell lung cancer

    phase 1 small molecule active

    1 trial

  15. Chemophase

    HALOZYME THERAPEUTICS, INC.

    Superficial Bladder Cancer

    phase 1 small molecule completed

    1 trial

  16. Chimeric antigen receptor T cell

    The First People's Hospital of Lianyungang

    Pancreatic Cancer

    phase 1 small molecule active

    1 trial

  17. Ciforadenant

    Corvus Pharmaceuticals

    Renal Cell Cancer

    phase 1 small molecule completed

    1 trial

  18. Cisplatin

    AstraZeneca

    Inoperable Locally Advanced or Metastatic Biliary Tract Cancer

    phase 1 small molecule terminated

    1 trial

  19. Cisplatin

    BioMarin Pharmaceutical Australia Pty Ltd

    Solid Tumors

    phase 1 small molecule terminated

    1 trial

  20. Cisplatin

    United Therapeutics Europe Ltd

    Advanced Cholangiocarcinoma

    phase 1 small molecule terminated

    1 trial

  21. Cisplatin

    Regeneron UK Limited

    Head and Neck Cancer

    phase 1 small molecule active

    1 trial

  22. Citarabina Hikma 2 g/20mL Soluzione Iniettabile, Idarubicin Hikma 1 mg/ml Injektionslösung, Cytarabine 100 mg/ml Solution for Injection or Infusion, Cytarabine 100 mg/ml Solution for Injection or Infusion, Daunoblastin® 20 mg Pulver zur Herstellung einer Infusions- oder Injektionslösung, JNJ-75276617, JNJ-75276617 (G022), Venclyxto 100 mg film-coated tablets, Idarubicin, Venclyxto 100 mg film-coated tablets, JNJ-75276617, JNJ-75276617 (G023), Azacitidine, JNJ-75276617, Citarabina Hikma 500mg/5mL Soluzione I

    Janssen-Cilag International N.V.

    Acute Myeloid Leukemia

    phase 1 small molecule active

    1 trial

  23. Click-cleavable imaging in HER2-positive cancers (CleavHER trial).

    Disc Medicine

    HER2-positive tumors

    phase 1 other active

    1 trial

  24. Clifutinib Besylate

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Acute Myeloid Leukemia

    phase 1 small molecule completed

    1 trial

  25. Clifutinib with fed state

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Acute Myeloid Leukemia in Children

    phase 1 small molecule completed

    1 trial

  26. Clinical study to evaluate the safety of investigational medicinal product called AD-O51.4 in patients with advanced malignancies

    Lacuna Pharma Pty Ltd

    Patients suffering from cancer without further treatment options.

    phase 1 other active

    1 trial

  27. Clinical trial evaluating the safety, tolerability, and preliminary efficacy of BNT116 alone and in combinations in patients with advanced non-small cell lung cancer

    BioNTech SE

    Advanced non-small cell lung cancer

    phase 1 other active

    1 trial

  28. Cobimetinib

    Cardiff Oncology

    Locally Advanced Pancreatic Ductal Adenocarcinoma

    phase 1 small molecule active

    1 trial

  29. Comparison between ABP 234 and Keytruda® (Pembrolizumab)

    Amgen

    Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

    phase 1 other active

    1 trial

  30. Concurrent chemotherapy

    Sun Yat-sen University

    Locally Advanced Lung Carcinoma

    phase 1 small molecule completed

    1 trial

  31. Conditioning chemotherapy followed by AbTCR (anti-CD19/CD22)-T cell infusion

    The First People's Hospital of Lianyungang

    Diffuse Large B Cell Lymphoma (DLBCL)

    phase 1 small molecule active

    1 trial

  32. Control Group

    Tvardi Therapeutics

    Squamous Cell Carcinoma of Head and Neck

    phase 1 small molecule terminated

    1 trial

  33. Cosibelimab

    TG THERAPEUTICS, INC.

    B-cell Non Hodgkin Lymphoma

    phase 1 small molecule terminated

    1 trial

  34. Custirsen, paclitaxel and carboplatin

    Teva Pharma GmbH

    Cancer

    phase 1 small molecule completed

    1 trial

  35. Cyclophosphamide

    Iovance Biotherapeutics B.V.

    Locally Advanced Melanoma

    phase 1 small molecule active

    1 trial

  36. Cyclophosphamide

    Nektar Therapeutics UK Limited

    Recurrent Diffuse Large B-Cell Lymphoma

    phase 1 small molecule active

    1 trial

  37. Cyclophosphamide

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 1 small molecule active

    1 trial

  38. Cyclophosphamide and Fludarabine

    Chongqing Precision Biotech Co., Ltd

    Lung Cancer, Nonsmall Cell, Recurrent

    phase 1 small molecule active

    1 trial

  39. DABRAFENIB MESYLATE, TMT212, CANAKINUMAB, DKY709, LXH254, TRAMETINIB DIMETHYL SULFOXIDE, NIR178, MCS110, LXH254, INC280, TMT212, PDR001, NIR178, PDR001, NIZ985, TRAMETINIB DIMETHYL SULFOXIDE, LAG525, NIR178, LXH254, DABRAFENIB MESYLATE

    Novartis Pharmaceuticals

    Different types of advanced cancer

    phase 1 small molecule active

    1 trial

  40. DAREONTM-9: A study to test how well different doses of BI 764532 are tolerated by people with small cell lung cancer when taken together with a single agent chemotherapy

    Boehringer Ingelheim

    relapsed/refractory extensive stage - small cell lung cancer (ES-SCLC)

    phase 1 other active

    1 trial

  41. DAREON™-7: A study to test how well different doses of BI 764532 in addition to chemotherapy are tolerated by people with advanced neuroendocrine cancers

    Boehringer Ingelheim

    Extra-pulmonary neuroendocrine carcinoma (epNEC), Neuroendocrine carcinoma (NEC) with unknown primary site, pulmonary Large cell neuroendocrine carcinoma (LCNEC)

    phase 1 other active

    1 trial

  42. DAREON™-8: A study to test how well different doses of BI 764532 in addition to standard of care are tolerated by people with advanced small cell lung cancer

    Boehringer Ingelheim

    Extensive-stage small cell lung carcinoma (ES-SCLC)

    phase 1 other active

    1 trial

  43. DCVac-L

    NORTHWEST BIOTHERAPEUTICS INC

    Ovarian Cancer

    phase 1 mab completed

    1 trial

  44. DEXTROMETHORPHANE ELERTE 1,5 mg/ml, sirop, AZD3470, AZD3470, Midazolam-ratiopharm® 2 mg/ml orale Lösung

    AstraZeneca AB

    Advanced/metastatic solid tumors that are MTAP deficient.

    phase 1 small molecule active

    1 trial

  45. DHAP

    Takeda

    Hodgkin Lymphoma

    phase 1 small molecule active

    1 trial

  46. DS-1205c

    Daiichi Sankyo

    Non-small Cell Lung Cancer (NSCLC)

    phase 1 small molecule terminated

    1 trial

  47. DT2216

    United Therapeutics Europe Ltd

    Ovarian Cancer

    phase 1 small molecule active

    1 trial

  48. Darlifarnib

    Kura Oncology

    Solid Tumors With HRAS Alterations

    phase 1 small molecule active

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,568 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.